Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of pharmacologic therapy, including intravitreal injections of anti-VEGF ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

Generally, laser treatment of CNV in PM is more difficult than the treatment of CNV in age-related macular degeneration. The causes may be due to hypopigmentation of the fundus that reduces laser ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

However, bevacizumab is not currently licensed for neovascular age-related macular degeneration (nAMD). Our study is the first trial-based economic ... 5 IVAN also compared discontinuous (as-needed) ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...